^
    Back
    Association details:
    Biomarker:ASXL1 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:azacitidine (DNMT inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    Excerpt:
    ...Acute myeloid leukemia with either Flt-3, TET-2, p53, DNMT3A, or ASXL1 mutation, mutations of genes involved in the chromatin/spliceosome category (EZH2, SRSF2, U2AF1, ZRSR2), BCOR, and RUNX1, as well as MLL rearrangement, EVI1 overexpression in complete morphologic remission; or 3....
    Trial ID:
    NCT02497404
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Blood Cancer J
    Title:

    ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

    Published date:
    09/21/2021
    Excerpt:
    Upon treatment with VEN, mutant cells demonstrated increased growth inhibition. In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA.
    DOI:
    10.1038/s41408-021-00541-0
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    Published date:
    07/22/2021
    Excerpt:
    ASXL1DEL /ASXL1MUT patients were correlated by univariable analysis with a worse response to AZA.
    DOI:
    10.1111/bjh.17675